Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
about
Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumorsPredictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerHeterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma.Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancerPost-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation.Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors.Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature.Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).The continued EGFR-TKI with cytotoxic chemotherapy at progression-poison or medicine?
P2860
Q28077504-A956047A-00E6-4A0A-A91A-48DCC6DE46D8Q33567383-CFF89DF3-0926-4B9C-A507-DC926D487AE7Q33710152-B1AB088F-20AA-43A9-BECB-5E1520A89786Q34293223-6EF1B6CC-6FDA-40CD-9987-C09FD84C379EQ35663566-BB26DDA8-245F-48F9-9CCD-E075D3685DFBQ36187118-E782A46A-B94F-4CA7-BBF2-619BC2B915EDQ36247912-1FA42C16-A2A8-444A-96E9-66B890976421Q36582368-A880D731-6DD3-4CAA-8AD5-2DBEB03D2961Q37329579-F392747E-CA73-4020-A789-6C36576E4A43Q37575209-34F41C94-F554-4811-93F9-CA4752700052Q50736135-B6CB0374-529D-4F2D-9C72-94389F0E93C3Q52682448-E358F606-9C37-40EB-A728-B1250358A1BEQ53217202-BC3D153C-17AE-41E8-9FC8-87593F2A8097Q55223055-2909CA59-6616-4427-9DA6-A9E63CE269DA
P2860
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of Non-small Cell Lu ...... ptor Tyrosine Kinase Inhibitor
@en
Treatment of Non-small Cell Lu ...... tor Tyrosine Kinase Inhibitor.
@nl
type
label
Treatment of Non-small Cell Lu ...... ptor Tyrosine Kinase Inhibitor
@en
Treatment of Non-small Cell Lu ...... tor Tyrosine Kinase Inhibitor.
@nl
prefLabel
Treatment of Non-small Cell Lu ...... ptor Tyrosine Kinase Inhibitor
@en
Treatment of Non-small Cell Lu ...... tor Tyrosine Kinase Inhibitor.
@nl
P2093
P2860
P356
P1476
Treatment of Non-small Cell Lu ...... ptor Tyrosine Kinase Inhibitor
@en
P2093
Jae Cheol Lee
Kye Young Lee
Seung Hun Jang
Young-Chul Kim
P2860
P356
10.4143/CRT.2013.45.2.79
P577
2013-06-30T00:00:00Z